• Vaccine Name: Herpes simplex virus type 1 DNA vaccine encoding GC
• Target Pathogen: Herpes simplex virus type 1 and 2
• Target Disease: Herpes
• Vaccine Ontology ID: VO_0011408
• Type: DNA vaccine
• Status: Research
• Antigen: Herpes simplex virus type 1 envelope glycoprotein C
• UL44 from HSV-1 gene engineering:
  • Type: DNA vaccine construction
  • Description: The HSV-1 KOS gC gene was isolated by PCR. Each gene was initially cloned into a TA cloning vector and then into a eukaryotic plasmic expression vector that uses the cytomegalovirus immediate-early promoter for expression (pRc/CMV for gC) (Nass et al., 1998).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000301

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Groups of 5 BALB/cByJ mice received 100-uL injections of purified plasmids into the quadriceps muscles of the hind legs. In most cases, injections were 3 weeks apart; blood samples were taken from the tail vein 1 day before injection or challenge, and approximately equal volumes of blood from individual mice were pooled within a group (Nass et al., 1998).
• Challenge Protocol: Three weeks after the final injection, mice were challenged ip with 5 x 10^4 pfu of HSV-1 McKrae, which was ~10 LD50S, as determied in BALB/cByJ mice (Nass et al., 1998).
• Efficacy: Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10^4 pfu) with gC (UL44) or gE plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge (Nass et al., 1998).